Sellas Life Sciences (SLS) gained as Commonwealth Equity Services increased its stake by 32% ahead of a Phase 3 AML trial milestone. The firm holds "Magnificent Seven" stocks. CEO Angelos Stergiou reaffirmed confidence in the trial's commercial potential. SLS seeks approval to expand its equity plan by 20 million shares. The stock jumped over 9% Monday.